Life Sciences

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
21 July 2020

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...

Read the press release
MedinCell announces the great success of its capital increase and raises 15.6 M€
17 June 2020

MedinCell announces the great success of its capital increase and raises 15.6 M€

MedinCell (FR0004065605 - MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas (the...

Read more
European Venture Capital Firm Seventure Partners renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare the next growth phase
28 May 2019

European Venture Capital Firm Seventure Partners renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare the next growth phase

Domain Therapeutics announces today that it has secured a €3.5M ($3.9M) investment from existing shareholder Seventure Partners, to accelerate its next growth phase. Since...

Read the press release
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
26 October 2018

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies

Read the press release
Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products
2 November 2016

Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, announced today that the...

Read the press release
TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease
4 December 2014

TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory...

Read the press release